Drug Profile


Alternative Names: NSC 130181; SR 259075; SR 4233; SR 4317; SR 4330; Tirazone; WIN 59075

Latest Information Update: 07 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SRI International; Stanford Cancer Institute
  • Developer SRI International; Teclison
  • Class Antineoplastics; Radiation-sensitising agents; Reducing agents; Small molecules; Triazines
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cervical cancer
  • Phase I Hepatocellular carcinoma
  • Discontinued Glioma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 12 May 2017 Teclison plans a phase II trial for Hepatocellular carcinoma in USA (NCT03145558)
  • 01 Sep 2014 Phase-I clinical trials in Hepatocellular carcinoma in Taiwan (IV)
  • 18 Aug 2014 Phase-III clinical trials in Cervical cancer in USA before August 2014 (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top